Medical College Students at MBBS and Community Medicine
CM: TB and HIV
- National TB-HIV Collaborative Framework
- Intensified TB Case Finding [ICF] in HIV testing Settings
- HIV testing of individuals with presumed or confirmed TB
- ART For TB-HIV Patients
- Immune Reconstitution Inflammatory Syndrome [IRIS]
- Co-trimoxazole prophylactic therapy in persons with HIV and TB coinfection
- Isoniazid Preventive Therapy [IPT] in People Living with HIV [PLHIV]
- Linkage to TB-HIV services in the private sector
- Prevention of TB in facilities caring for HIV-infected persons
CM: Monitoring of Treatment
- Monitoring indicator for TB Treatment outcome
- Monitoring indicators related to DR-TB Treatment
- NTEP Performance Indicator - Treatment Success Rate
- NTEP Performance Indicator – Percentage Of Multidrug-resistant [MDR]/ Rifampicin-resistant [RR] Patients Initiated on Treatment Out of Totally Diagnosed
- RCA for low performance in in Percentage Treatment initiation of RR/MDR-TB Cases
- DR-TB Treatment Register
- Follow-Up Register
- DRTB Follow Up Register
CM: ADRs to ATT
- Adverse Drug Reactions [ADRs]
- Types of ADR of TB Treatment
- Management of Adverse Drug Reactions [ADRs] of TB Treatment
- Active TB Drug Safety Monitoring [aDSM]
- Pharmacovigilance in NTEP
- Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen
- Adverse Drug Events: H Mono/Poly DR-TB Regimen
- ADRs to Second Line Treatment
- Management of ADR: Rash, Allergy and Anaphylaxis Reaction
- Management of DR-TB ADR: Gastritis, abdominal pain
- Management of DR-TB ADR: Diarrhoea and/or Flatulence
- Management of DR-TB ADR: Hepatitis
- Management of DR-TB ADR: Giddiness
- Management of DR-TB ADR: QT Prolongation
- Management of DR-TB ADR: Hematological Abnormalities
- Management of DR-TB ADR: Hypothyroidism
- Management of DR-TB ADR: Arthralgia
- Management of DR-TB ADR: Peripheral Neuropathy
- Management of DR-TB ADR: Psychotic Symptoms
- Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity]
- Management of DR-TB ADR: Vestibular Toxicity
CM: Adherence Management
- TB Treatment Adherence
- Importance of Treatment adherence
- Recording and Monitoring Adherence
- Digital Adherence Monitoring Technologies
- Directly Observed Treatment [DOT]
- Recording Adherence in Treatment card
- Recording Adherence using TB Arogya Sathi Application
- 99 DOTS- Features and Benefits
- 99 DOTS- Envelopes
- 99 DOTS- Envelope Dispensing Process
- 99 DOTS- Initiating adherence monitoring of the patient
- 99 DOTS- Self Reporting Adherence
- Medication Event Reminder Monitor [MERM] Boxes
- MERM Patient Register
- Monitoring of Adherence by NTEP Staff
- Adherence Summary Dashboard
- Management of Patients with Treatment Interruptions
- Adherence Register
CM: Longer Oral M/XDR-TB Regimen
- Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen
- Eligibility Criteria for Longer Oral M/XDR-TB Regimen
- Longer Oral M/XDR-TB: Regimen and Duration
- Treatment Extension in Longer Oral M/XDR-TB Regimen
- Dosages of M/XDR-TB Drugs for Adult in Longer Oral M/XDR-TB Regimen
- Details of Replacement Sequence of Drugs in Longer Oral M/XDR-TB Regimen
- Follow up sputum examination for Longer Oral M/XDR-TB DR-TB Regimen
CM: Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE]
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen: Evidence
- Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment
- Shorter oral Bedaquiline-containing MDR/RR-TB regimen
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Dosage of Drugs for Adults
- Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Replacement Sequence of Drugs
- Follow up sputum examination for Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
- List of Drugs that can be Used Safely or Avoided along with Bedaquiline
CM: Isoniazid [H] Mono/Poly DR-TB Regimen
- Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation
- EVIDENCE FOR ISONIAZID[H] MONO/POLY DR-TB REGIMEN
- Eligibility Criteria for H Mono/poly DR-TB Regimen
- Eligibility Criteria for H Mono/poly DR-TB Regimen
- Replacement Sequence in the H Mono/Poly DR-TB
- Follow up sputum examination for Isoniazid [H] Mono/Poly DR-TB Regimen